Analysts Offer Predictions for Verona Pharma FY2026 Earnings

Verona Pharma plc (NASDAQ:VRNA) – Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Verona Pharma in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the company will post earnings per share of $12.56 for the year. Cantor Fitzgerald has a “Overweight” rating and a $80.00 price objective on the stock. The consensus estimate for Verona Pharma’s current full-year earnings is ($1.95) per share.

Several other brokerages have also recently weighed in on VRNA. Wells Fargo & Company upped their price target on Verona Pharma from $93.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, April 30th. Cowen began coverage on Verona Pharma in a research note on Monday, April 28th. They issued a “buy” rating on the stock. TD Cowen initiated coverage on Verona Pharma in a report on Monday, April 28th. They set a “buy” rating and a $100.00 price objective for the company. Roth Capital set a $83.00 price target on shares of Verona Pharma in a report on Friday, February 28th. Finally, HC Wainwright upped their target price on shares of Verona Pharma from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, June 2nd. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $82.13.

Verona Pharma Trading Up 2.5%

NASDAQ:VRNA opened at $86.78 on Wednesday. Verona Pharma has a 1 year low of $12.20 and a 1 year high of $88.36. The stock’s fifty day moving average price is $68.83 and its two-hundred day moving average price is $59.33. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The company has a market cap of $7.04 billion, a P/E ratio of -45.20 and a beta of 0.21.

Verona Pharma (NASDAQ:VRNA) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Geneos Wealth Management Inc. raised its holdings in Verona Pharma by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company’s stock worth $40,000 after buying an additional 193 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Verona Pharma by 14.0% in the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company’s stock worth $117,000 after purchasing an additional 225 shares during the last quarter. Townsquare Capital LLC lifted its holdings in shares of Verona Pharma by 1.9% during the fourth quarter. Townsquare Capital LLC now owns 17,958 shares of the company’s stock valued at $834,000 after purchasing an additional 332 shares in the last quarter. NBC Securities Inc. bought a new stake in Verona Pharma in the 1st quarter worth about $34,000. Finally, Advisors Preferred LLC raised its position in Verona Pharma by 65.4% in the 1st quarter. Advisors Preferred LLC now owns 1,599 shares of the company’s stock worth $94,000 after buying an additional 632 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

Insider Transactions at Verona Pharma

In other news, insider Kathleen A. Rickard sold 34,384 shares of the stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $8.98, for a total transaction of $308,768.32. Following the completion of the sale, the insider now directly owns 2,660,656 shares in the company, valued at approximately $23,892,690.88. This represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Andrew Fisher sold 26,072 shares of the company’s stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $8.98, for a total value of $234,126.56. Following the transaction, the general counsel now directly owns 359,993 shares of the company’s stock, valued at $3,232,737.14. The trade was a 6.75% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,085,800 shares of company stock worth $10,014,481. Company insiders own 4.80% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.